{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:54:02Z","timestamp":1787316842916,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010570","name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["iCA_13-01-2020"],"award-info":[{"award-number":["iCA_13-01-2020"]}],"id":[{"id":"10.13039\/501100010570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010570","name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["iCA_13-01-2020"],"award-info":[{"award-number":["iCA_13-01-2020"]}],"id":[{"id":"10.13039\/501100010570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004871","name":"Technische Universit\u00e4t Braunschweig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004871","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Corneal exposure to trophozoites of\n                    <jats:italic>Acanthamoeba<\/jats:italic>\n                    spp. may lead to\n                    <jats:italic>Acanthamoeba<\/jats:italic>\n                    keratitis (AK)\u2014a rare, but sight-threatening disease\u2014with a risk of recurrence due to residual stromal cysts. With polyhexanide (PHMB) and chlorhexidine (CHX) often constituting the standard regimen of therapy, polymeric compounds for the treatment of AK have shifted into the focus of research. In this study, the effectiveness of four 4,4\u2032-trimethylenedipyridinium (TMDPy), 4,4\u2032-trimethylenedipiperidinium (TMDPi)-based polymers, and polyquaternium-1 on\n                    <jats:italic>Acanthamoeba<\/jats:italic>\n                    trophozoites and cysts has been evaluated and their interactions with cells characterized. A total eradication assay was performed to assess the efficacy of the investigated compounds, while its effects on host cells and the barrier integrity of epithelial cell layers were evaluated via MTT assays and the relative reduction of transepithelial electrical resistance (TEER). The 4,4\u2032-trimethylenedipyridinium and 4,4\u2032-trimethylenedipiperidinium-based compounds exhibited a high efficacy against trophozoites (&lt;\u200920\u00a0\u00b5g\/mL), while the cysticidal activity proved to be considerably lower (&lt;\u2009500\u00a0\u00b5g\/mL). The detrimental effect on viability of host cells was time-dependent, while a near total reduction of TEER was observed within the first 15\u00a0min of exposure, leading to the conclusion that this class of polymers may not be adequate for therapeutic purposes, but possibly find use as preservatives for contact lens storage solutions.\n                  <\/jats:p>","DOI":"10.1007\/s00436-025-08537-6","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:25:05Z","timestamp":1755656705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro evaluation of 4,4\u2032-trimethylenedipyridinium and 4,4\u2032-trimethylenedipiperidinium-based polycationic polymers against Acanthamoeba hatchetti"],"prefix":"10.1007","volume":"124","author":[{"given":"Tomas","family":"Rimkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"8537_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/cmdc.201600546","volume":"12","author":"SE Al-Khalifa","year":"2017","unstructured":"Al-Khalifa SE, Jennings MC, Wuest WM, Minbiole KPC (2017) The development of next-generation pyridinium-based multiQAC antiseptics. ChemMedChem 12:280\u2013283. https:\/\/doi.org\/10.1002\/cmdc.201600546","journal-title":"ChemMedChem"},{"key":"8537_CR2","first-page":"614","volume":"36","author":"K Araki-Sasaki","year":"1995","unstructured":"Araki-Sasaki K, Ohashi Y, Sasabe T, Hayashi K, Watanabe H, Tano Y, Handa H (1995) An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci 36:614\u2013621","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8537_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/09273948.2019.1695853","volume":"29","author":"E Avdagic","year":"2021","unstructured":"Avdagic E, Chew HF, Veldman P, Tu EY, Jafri M, Doshi R, Boggild AK, Reidy JJ, Farooq AV (2021) Resolution of Acanthamoeba keratitis with adjunctive use of oral miltefosine. Ocul Immunol Inflamm 29:278\u2013281. https:\/\/doi.org\/10.1080\/09273948.2019.1695853","journal-title":"Ocul Immunol Inflamm"},{"key":"8537_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/bjophthalmol-2018-312544","volume":"102","author":"N Carnt","year":"2018","unstructured":"Carnt N, Hoffman JJ, Verma S, Hau S, Radford CF, Minassian DC, Dart JKG (2018) Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. Br J Ophthalmol 102:1621\u20131628. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312544","journal-title":"Br J Ophthalmol"},{"key":"8537_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0005-2736(85)90224-X","volume":"820","author":"D Carrier","year":"1985","unstructured":"Carrier D, Dufourcq J, Faucon J-F, P\u00e9zolet M (1985) A fluorescence investigation of the effects of polylysine on dipalmitoylphosphatidylglycerol bilayers. Biochim Biophys Acta 820:131\u2013139. https:\/\/doi.org\/10.1016\/0005-2736(85)90224-X","journal-title":"Biochim Biophys Acta"},{"key":"8537_CR6","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S1473-3099(20)30933-6","volume":"22","author":"GL Damhorst","year":"2022","unstructured":"Damhorst GL, Watts A, Hernandez-Romieu A, Mel N, Palmore M, Ali IKM, Neill SG, Kalapila A, Cope JR (2022) Acanthamoeba castellanii encephalitis in a patient with AIDS: a case report and literature review. Lancet Infect Dis 22:e59\u2013e65. https:\/\/doi.org\/10.1016\/S1473-3099(20)30933-6","journal-title":"Lancet Infect Dis"},{"key":"8537_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ophtha.2023.09.031","volume":"131","author":"JKG Dart","year":"2024","unstructured":"Dart JKG, Papa V, Rama P, Knutsson KA, Ahmad S, Hau S, Sanchez S, Franch A, Birattari F, Leon P, Fasolo A, Kominek EM, Jadczyk-Sorek K, Carley F, Hossain P, Minassian DC (2024) The orphan drug for Acanthamoeba keratitis (ODAK) trial: PHMB 0.08% (polihexanide) and placebo versus PHMB 0.02% and propamidine 0.1. Ophthalmology 131:277\u2013287. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.031","journal-title":"Ophthalmology"},{"issue":"1","key":"8537_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/opo.12752","volume":"41","author":"AG de Lacerda","year":"2021","unstructured":"de Lacerda AG, Lira M (2021) Acanthamoeba keratitis: a review of biology, pathophysiology and epidemiology. Ophthalmic Physiol Opt 41(1):116\u2013135. https:\/\/doi.org\/10.1111\/opo.12752","journal-title":"Ophthalmic Physiol Opt"},{"key":"8537_CR9","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1128\/AAC.42.9.2232","volume":"42","author":"S Gatti","year":"1998","unstructured":"Gatti S, Cevini C, Bruno A, Penso G, Rama P, Scaglia M (1998) In vitro effectiveness of povidone-iodine on Acanthamoeba isolates from human cornea. Antimicrob Agents Chemother 42:2232\u20132234","journal-title":"Antimicrob Agents Chemother"},{"key":"8537_CR10","doi-asserted-by":"publisher","unstructured":"Heredero-Bermejo I, Copa-Pati\u00f1o JL, Soliveri J, Garc\u00eda-Gallego S, Rasines B, G\u00f3mez R, La Mata FJ de, P\u00e9rez-Serrano J (2013) In vitro evaluation of the effectiveness of new water-stable cationic carbosilane dendrimers against Acanthamoeba castellanii UAH-T17c3 trophozoites. Parasitol Res 112:961\u2013969. https:\/\/doi.org\/10.1007\/s00436-012-3216-z","DOI":"10.1007\/s00436-012-3216-z"},{"key":"8537_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.100555","volume":"16","author":"KE Hirabayashi","year":"2019","unstructured":"Hirabayashi KE, Lin CC, Ta CN (2019) Oral miltefosine for refractory Acanthamoeba keratitis. Am J Ophthalmol Case Rep 16:100555. https:\/\/doi.org\/10.1016\/j.ajoc.2019.100555","journal-title":"Am J Ophthalmol Case Rep"},{"key":"8537_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0005-2736(90)90339-P","volume":"1026","author":"T Ikeda","year":"1990","unstructured":"Ikeda T, Yamaguchi H, Tazuke S (1990) Phase separation in phospholipid bilayers induced by biologically active polycations. Biochim Biophys Acta 1026:105\u2013112. https:\/\/doi.org\/10.1016\/0005-2736(90)90339-P","journal-title":"Biochim Biophys Acta"},{"key":"8537_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2672.1997.tb03304.x","volume":"82","author":"W Khunkitti","year":"1997","unstructured":"Khunkitti W, Lloyd D, Furr JR, Russell AD (1997) Aspects of the mechanisms of action of biguanides on trophozoites and cysts of Acanthamoeba castellanii. J Appl Microbiol 82:107\u2013114","journal-title":"J Appl Microbiol"},{"key":"8537_CR14","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1167\/iovs.13-11927","volume":"54","author":"S Kilvington","year":"2013","unstructured":"Kilvington S, Lam A (2013) Development of standardized methods for assessing biocidal efficacy of contact lens care solutions against Acanthamoeba trophozoites and cysts. Invest Ophthalmol Vis Sci 54:4527\u20134537. https:\/\/doi.org\/10.1167\/iovs.13-11927","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8537_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101499","volume":"26","author":"G Li","year":"2022","unstructured":"Li G, Shekhawat N (2022) Acanthamoeba epitheliopathy: importance of early diagnosis. Am J Ophthalmol Case Rep 26:101499. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101499","journal-title":"Am J Ophthalmol Case Rep"},{"key":"8537_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41598-020-80222-3","volume":"11","author":"W List","year":"2021","unstructured":"List W, Glatz W, Riedl R, Mossboeck G, Steinwender G, Wedrich A (2021) Evaluation of Acanthamoeba keratitis cases in a tertiary medical care centre over 21 years. Sci Rep 11:1036. https:\/\/doi.org\/10.1038\/s41598-020-80222-3","journal-title":"Sci Rep"},{"key":"8537_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/md17070420","volume":"17","author":"J Lorenzo-Morales","year":"2019","unstructured":"Lorenzo-Morales J, D\u00edaz-Marrero AR, Cen-Pacheco F, Sifaoui I, Reyes-Batlle M, Souto ML, Hern\u00e1ndez Daranas A, Pi\u00f1ero JE, Fern\u00e1ndez JJ (2019) Evaluation of oxasqualenoids from the red alga Laurencia viridis against Acanthamoeba. Mar Drugs 17:420. https:\/\/doi.org\/10.3390\/md17070420","journal-title":"Mar Drugs"},{"key":"8537_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/ICO.0000000000000642","volume":"34","author":"E-K Moon","year":"2015","unstructured":"Moon E-K, Hong Y, Chung D-I, Goo Y-K, Kong H-H (2015) Potential value of cellulose synthesis inhibitors combined with PHMB in the treatment of Acanthamoeba keratitis. Cornea 34:1593\u20131598","journal-title":"Cornea"},{"key":"8537_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-62934-8","volume":"10","author":"R Mooney","year":"2020","unstructured":"Mooney R, Masala M, Martial T, McGinness C, Henriquez FL, Williams RAM (2020) Alkyl-carbon chain length of two distinct compounds and derivatives are key determinants of their anti-Acanthamoeba activities. Sci Rep 10:1\u201311. https:\/\/doi.org\/10.1038\/s41598-020-62934-8","journal-title":"Sci Rep"},{"key":"8537_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00055","volume":"8","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, Barman S, Mukherjee R, Haldar J (2020) Amphiphilic cationic macromolecules highly effective against multi-drug resistant gram-positive bacteria and fungi with no detectable resistance. Front Bioeng Biotechnol 8:55. https:\/\/doi.org\/10.3389\/fbioe.2020.00055","journal-title":"Front Bioeng Biotechnol"},{"key":"8537_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00003226-200203000-00016","volume":"21","author":"S Narasimham","year":"2002","unstructured":"Narasimham S, Madhavan HN, Lily TK (2002) Development and application of an in vitro susceptibility test for Acanthamoeba species isolated from keratitis to polyhexamethylene biguanide and chlorhexidine. Cornea 21:203\u2013205","journal-title":"Cornea"},{"key":"8537_CR22","unstructured":"Orphanet: Research and trials (n.d.)\u00a0https:\/\/www.orpha.net\/en\/research-trials\/clinical-trials?orphaCode=67043anddiseaseName=Amoebic%20keratitis. Accessed 27 Mar 2025"},{"key":"8537_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bjophthalmol-2019-314485","volume":"104","author":"V Papa","year":"2020","unstructured":"Papa V, Rama P, Radford C, Minassian DC, Dart JKG (2020) Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol 104:575\u2013581. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314485","journal-title":"Br J Ophthalmol"},{"key":"8537_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222092","volume":"14","author":"AC Randag","year":"2019","unstructured":"Randag AC, van Rooij J, van Goor AT, Verkerk S, Wisse RPL, Saelens IEY, Stoutenbeek R, van Dooren BTH, Cheng YYY, Eggink CA (2019) The rising incidence of Acanthamoeba keratitis: a 7-year nationwide survey and clinical assessment of risk factors and functional outcomes. PLoS One 14:e0222092. https:\/\/doi.org\/10.1371\/journal.pone.0222092","journal-title":"PLoS One"},{"key":"8537_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv104","volume":"2","author":"A Salameh","year":"2015","unstructured":"Salameh A, Bello N, Becker J, Zangeneh T (2015) Fatal granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with kidney transplant: a case report. Open Forum Infect Dis 2:ofv104. https:\/\/doi.org\/10.1093\/ofid\/ofv104","journal-title":"Open Forum Infect Dis"},{"key":"8537_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1550-7408.1993.tb06108.x","volume":"40","author":"FL Schuster","year":"1993","unstructured":"Schuster FL (1993) Comparative effects of selected azole compounds on trophic and cystic stages of Acanthamoeba polyphaga. J Euk Microbiol 40:563\u2013569","journal-title":"J Euk Microbiol"},{"key":"8537_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1550-7408.2005.00082.x","volume":"53","author":"FL Schuster","year":"2006","unstructured":"Schuster FL, Guglielmo BJ, Visvesvara GS (2006) In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 53:121\u2013126. https:\/\/doi.org\/10.1111\/j.1550-7408.2005.00082.x","journal-title":"J Eukaryot Microbiol"},{"key":"8537_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.15585\/mmwr.mm6819a6","volume":"68","author":"BA Scruggs","year":"2019","unstructured":"Scruggs BA, Quist TS, Salinas JL, Greiner MA (2019) Notes from the field: Acanthamoeba keratitis cases - Iowa, 2002\u20132017. Morb Mortal Wkly Rep 68:448\u2013449","journal-title":"Morb Mortal Wkly Rep"},{"key":"8537_CR29","doi-asserted-by":"publisher","unstructured":"Shi L, Stachon T, Latta L, Elhawy MI, Gunaratnam G, Orosz E, Kiderlen AF, Seitz B, Bischoff M, Szentm\u00e1ry N (2019) Comparison of in vitro assays to study the effectiveness of antiparasitics against Acanthamoeba castellani trophozoites and cysts. Acta Microbiol Immunol Hung. https:\/\/doi.org\/10.1556\/030.66.2019.029","DOI":"10.1556\/030.66.2019.029"},{"key":"8537_CR30","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1080\/14787210.2021.1924673","volume":"19","author":"B Shing","year":"2021","unstructured":"Shing B, Balen M, McKerrow JH, Debnath A (2021) Acanthamoeba keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs. Expert Rev Anti-Infect Ther 19:1427\u20131441. https:\/\/doi.org\/10.1080\/14787210.2021.1924673","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"8537_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/pathogens8030130","volume":"8","author":"I Sifaoui","year":"2019","unstructured":"Sifaoui I, Rodr\u00edguez-Exp\u00f3sito RL, Reyes-Batlle M, Rizo-Liendo A, Pi\u00f1ero JE, Bazzocchi IL, Lorenzo-Morales J, Jim\u00e9nez IA (2019) Ursolic acid derivatives as potential agents against Acanthamoeba spp. Pathogens 8:130. https:\/\/doi.org\/10.3390\/pathogens8030130","journal-title":"Pathogens"},{"key":"8537_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/0035-9203(80)90209-6","volume":"74","author":"AR Stevens","year":"1980","unstructured":"Stevens AR, Willaert E (1980) Drug sensitivity and resistance of four Acanthamoeba species. Trans R Soc Trop Med Hyg 74:806\u2013808","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"8537_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ophtha.2005.10.041","volume":"113","author":"X Sun","year":"2006","unstructured":"Sun X, Zhang Y, Li R, Wang Z, Luo S, Gao M, Deng S, Chen W, Jin X (2006) Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology 113:412\u2013416. https:\/\/doi.org\/10.1016\/j.ophtha.2005.10.041","journal-title":"Ophthalmology"},{"key":"8537_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijpddr.2017.09.002","volume":"7","author":"A Taravaud","year":"2017","unstructured":"Taravaud A, Loiseau PM, Pomel S (2017) In vitro evaluation of antimicrobial agents on Acanthamoeba sp. and evidence of a natural resilience to amphotericin B. Int J Parasitol Drugs Drug Resist 7:328\u2013336. https:\/\/doi.org\/10.1016\/j.ijpddr.2017.09.002","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"8537_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-018-2536-9","volume":"36","author":"D von Deylen","year":"2018","unstructured":"von Deylen D, Dreher C, Seidelmann O, Reichl S (2018) New classes of polycationic compounds as preservatives for ophthalmic formulations. Pharm Res 36:11. https:\/\/doi.org\/10.1007\/s11095-018-2536-9","journal-title":"Pharm Res"},{"key":"8537_CR36","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1128\/AAC.39.7.1596","volume":"39","author":"S Zanetti","year":"1995","unstructured":"Zanetti S, Fiori PL, Pinna A, Usai S, Carta F, Fadda G (1995) Susceptibility of Acanthamoeba castellanii to contact lens disinfecting solutions. Antimicrob Agents Chemother 39:1596\u20131598. https:\/\/doi.org\/10.1128\/AAC.39.7.1596","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-025-08537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-025-08537-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-025-08537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:05:50Z","timestamp":1757048750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-025-08537-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["8537"],"URL":"https:\/\/doi.org\/10.1007\/s00436-025-08537-6","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}